CompletedNCT01810380
Brexpiprazole Compared With Quetiapine or Placebo for Acute Schizophrenia
About this title
Read the official source — NCT01810380Researchers compared Brexpiprazole and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared Brexpiprazole and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- EscondidoSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 468
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01810380
- Official title
Show the full official title
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Brexpiprazole and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Brexpiprazole and Quetiapine extended release.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia